Cargando…
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease
Autores principales: | Lukin, Dana J., Kumar, Anand, Hajifathalian, Kaveh, Sharaiha, Reem Z., Scherl, Ellen J., Longman, Randy S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the AGA Institute
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256492/ https://www.ncbi.nlm.nih.gov/pubmed/32479824 http://dx.doi.org/10.1053/j.gastro.2020.05.066 |
Ejemplares similares
-
Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination
por: Charilaou, Paris, et al.
Publicado: (2022) -
Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease
por: Gordon, Benjamin Langan, et al.
Publicado: (2022) -
Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022) -
Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020) -
Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)